Back

NurExone reports US$1.68 million Q2 loss and targets 2027 GMP batches

Verifying
  • NurExone reported second-quarter 2026 financial results and corporate milestones.
  • US$1.68 million was the company’s Q2 net loss, versus US$1.85 million in 2025.
  • Initial U.S. GMP exosome batches are targeted for the first half of 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.